Lilly's retatrutide beats Novo's Ozempic in head-to-head diabetes trial
The 'triple-G' candidate's win in a direct comparison strengthens Lilly's position in the obesity and diabetes market, where it is already competing with Novo's
Yahoo Finance · +11 outlets
US judge rejects Novo Nordisk bid to block Lilly's obesity drug advertising
The ruling is a setback in Novo's legal efforts to curb comparative advertising by its main GLP-1 rival.
BioPharma Dive · +14 outlets
Hanmi's Epe obesity drug launches in Korea, creating three-way race with Mounjaro and Wegovy
Korea's first domestically developed obesity treatment enters a market long dominated by imported GLP-1 drugs.
KED Global · +2 outlets
Supreme Court questions why most medicines escape India's price control regime, reserves order
The court is weighing the scope of India's drug price framework as it examines wide gaps between purchase prices and maximum retail prices.
Live Law · +7 outlets
India's NPPA cuts MRPs on hundreds of anti-cancer drug brands by up to 93%
The price revisions, effective November 9, expose large hospital and trade margins on oncology medicines.
ETV Bharat · +14 outlets
Trump signs executive order imposing 100% tariff on some pharmaceutical drugs
The move threatens drugmakers' import economics and could pressure global pharma supply chains.
France 24 · +11 outlets
FDA signals faster route for patient-specific gene edits, lifting PRME, BEAM, EDIT, NTLA and CRSP
A streamlined regulatory pathway could shorten development timelines for personalized gene-editing therapies.
TradingView · +2 outlets
Vanda's tradipitant shows positive results preventing GLP-1-induced vomiting
A treatment for a common GLP-1 side effect could improve tolerability of the fast-growing obesity drug class.
PR Newswire · +12 outlets
Moderna shares rise after strong Phase 3 melanoma vaccine results
Positive data for the mRNA cancer vaccine candidate boosts sentiment around Moderna's oncology pipeline and Iovance's melanoma focus.
Traders Union · +14 outlets
Artiva axes 94% of workforce and weighs strategic alternatives after two Phase IIa patient deaths
The cuts mark a severe setback for the cell therapy developer following safety events in an early-stage trial.
Genetic Engineering and Biotechnology Ne · +2 outlets
Pfizer's multiple myeloma therapy shows extended progression-free survival
The data support Pfizer's oncology push as it looks to offset declining COVID-related revenue.
Benzinga · +11 outlets
FDA advisers narrowly vote to add 6 peptides to drug compounding list
The vote could widen access to compounded versions of popular peptides, drawing scrutiny over safety and oversight.
PBS · +3 outlets
United Therapeutics wins FDA clearance to begin clinical trial of inhaled PAH treatment
The clearance advances an inhaled therapy for pulmonary arterial hypertension, a niche with high unmet need.
Yahoo Finance · +14 outlets
Korea's NPS shifts toward K-beauty and obesity drug plays, trims biotech risk
The pension fund's reallocation signals changing institutional appetite for Korean biotech and consumer health exposure.
Chosun
Global big pharma expands investment in China across drug development and manufacturing
Multinationals are deepening China ties even as policy and pricing pressures reshape the sector.
https://economy.ac/ · +14 outlets
Patients Cannot Be Weighed Against Commerce: Supreme Court Questions Huge Gap Between Medicine Purchase Prices and MRP
The court's scrutiny of medicine margins has implications for hospitals and pharmacy chains.
Law Trend · +6 outlets
Hanmi Pharmaceutical Q3 profit slides 31% as obesity drug rollout nears
The Korean drugmaker is banking on Epe sales and technology exports to drive a profit rebound.
Aju Press · +1 outlets
Rep. Marshall bought stock in obscure pharma company just before key FDA approval
The disclosure raises conflict-of-interest questions about congressional trading in health stocks.
Popular Information